Clinical Trial Update: Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase IIa trial of Ublituximab in relapsing forms of multiple sclerosis completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ublituximab (ublituximab)

Snippet

Sponsor: TG Therapeutics, Inc. | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2021-07-15